<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>403</serviceExecutionTime><Drug id="17824"><DrugName>R-fluoxetine</DrugName><DrugSynonyms><Name><Value>R-fluoxetine</Value></Name><Name><Value>(R)-Fluoxetine hydrochloride</Value></Name><Name><Value>100568-03-4</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>114247-09-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19858">Sunovion Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="15065">Bristol-Myers Squibb Co</Company><Company id="17810">Eli Lilly &amp; Co</Company><Company id="19858">Sunovion Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17824" type="Drug"><TargetEntity id="263642" type="siDrug">(R)-Fluoxetine</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="19858" type="Company"><TargetEntity id="4295907900" type="organizationId">Sunovion Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3" type="Action"><TargetEntity id="235" type="Mechanism">5-HT Reuptake Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="3">5-HT uptake inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6A4</Code><Name>SSRI antidepressants</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-28T13:17:17.000Z</LastModificationDate><ChangeDateLast>2017-02-02T00:00:00.000Z</ChangeDateLast><AddedDate>1998-05-08T11:34:20.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Sepracor and Lilly were developing (R)-&lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt;, a single-isomer version of Prozac (racemic &lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt;, qv), for the potential treatment of depression. By May 1999, it had entered phase II trials [&lt;ulink linkID="337315" linkType="reference"&gt;337315&lt;/ulink&gt;]; however, Lilly terminated the licensing agreement in October 2000, and Sepracor decided not to pursue further development at this time [&lt;ulink linkID="386245" linkType="reference"&gt;386245&lt;/ulink&gt;], [&lt;ulink linkID="436424" linkType="reference"&gt;436424&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development was suspended following Lilly's decision to terminate the licensing agreement, which was a result of clinical data which demonstrated a statistically significant increase in QTc prolongation. Sepracor believed that this was clinically insignificant; however, development of a lower dose would delay an NDA submission by 2 years, hence the company decided not to pursue further development [&lt;ulink linkID="386245" linkType="reference"&gt;386245&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;It entered phase I trials in October 1998, to evaluate the safety and efficacy of successively ascending doses of (R)-&lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt;, together with tolerability, combination therapy, special population and drug-drug interaction studies [&lt;ulink linkID="301439" linkType="reference"&gt;301439&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 1998, Sepracor entered into a license agreement with Lilly giving Lilly rights to exclusively develop and globally commercialize (R)-&lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt; [&lt;ulink linkID="308357" linkType="reference"&gt;308357&lt;/ulink&gt;], [&lt;ulink linkID="310387" linkType="reference"&gt;310387&lt;/ulink&gt;] and Lilly initiated phase II trials in 1999 [&lt;ulink linkID="360984" linkType="reference"&gt;360984&lt;/ulink&gt;]. These trials were hoped to provide the basis for an NDA filing in 2000 [&lt;ulink linkID="313095" linkType="reference"&gt;313095&lt;/ulink&gt;], [&lt;ulink linkID="361969" linkType="reference"&gt;361969&lt;/ulink&gt;]. As of April 2000, Lilly was anticipating the completion of the trials necessary for filing by 2001 [&lt;ulink linkID="363110" linkType="reference"&gt;363110&lt;/ulink&gt;]; Sepracor had predicted a launch date no earlier than 2001 [&lt;ulink linkID="299575" linkType="reference"&gt;299575&lt;/ulink&gt;], [&lt;ulink linkID="361969" linkType="reference"&gt;361969&lt;/ulink&gt;]. Lilly terminated the agreement in October 2000, following the findings that QTc prolongation was statistically significantly increased [&lt;ulink linkID="386245" linkType="reference"&gt;386245&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2000, Morgan Stanley Dean Witter was predicting an NDA filing in 2002 [&lt;ulink linkID="373870" linkType="reference"&gt;373870&lt;/ulink&gt;]. In August 2000, Merrill Lynch expected US filing to occur in late 2001 [&lt;ulink linkID="383230" linkType="reference"&gt;383230&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2000, Forest Laboratories presented the results of a study comparing the transporter binding profiles of R-flluoxetine and S-&lt;ulink linkID="2822" linkType="Drug"&gt;citalopram&lt;/ulink&gt; (LU-26-054) (qv) at the 153rd annual meeting of the American Psychiatric Association. Both the R- and S-enantiomers of &lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt; were found to have equally potent activity for inhibiting serotonin reuptake, although the breakdown product of &lt;ulink linkID="17824" linkType="Drug"&gt;R-fluoxetine&lt;/ulink&gt; is relatively inactive [&lt;ulink linkID="366769" linkType="reference"&gt;366769&lt;/ulink&gt;], [&lt;ulink linkID="377008" linkType="reference"&gt;377008&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2000, data on &lt;ulink linkID="17824" linkType="Drug"&gt;R-fluoxetine&lt;/ulink&gt; were presented at the Society for Neuroscience 30th Annual Meeting. Pigeons were trained to keypeck on a multiple fixed ratio 30 schedule. In the presence of a red stimulus light, pecking was maintained by food presentation and simultaneously suppressed by electric shock. &lt;ulink linkID="17824" linkType="Drug"&gt;R-fluoxetine&lt;/ulink&gt; (0.01 to 1.0 mg/kg) increased punished responding to almost 600% of control, without having an effect on the unpunished responding [&lt;ulink linkID="390729" linkType="reference"&gt;390729&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt;(R)-&lt;ulink linkID="17558" linkType="Drug"&gt;Fluoxetine&lt;/ulink&gt;, a specific serotonin reuptake inhibitor (SSRI), has been shown in preclinical studies to have the potential for treatment flexibility due to its shorter half-life, which may result in the ability to switch drug therapies more rapidly. These same properties may offer greater suitability for treating elderly, pediatric and adolescent patient groups. (R)-&lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt; also could potentially be well suited for treatment of new indications for SSRIs, such as premenstrual syndrome and treatment of patients with depression following an acute myocardial infarction.&lt;/para&gt;&lt;para&gt;The development plan depended on &lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt; patent protection beyond its expiration in 2001. If the patent protection was threatened before 2004, clinical development of (R)-&lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt; could be accelerated [&lt;ulink linkID="310213" linkType="reference"&gt;310213&lt;/ulink&gt;]. In line with the licensing of other launched compounds, Sepracor have also claimed a patent on the S-isomer of &lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt; [&lt;ulink linkID="385807" linkType="reference"&gt;385807&lt;/ulink&gt;]. Sepracor has been issued US-05708035 covering the use of (R)-&lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt; to treat depression [&lt;ulink linkID="284630" linkType="reference"&gt;284630&lt;/ulink&gt;]. The synthesis of specific isomers of &lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt; is disclosed by Sepracor in US-05936124 [&lt;ulink linkID="345727" linkType="reference"&gt;345727&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;It had been reported in late 1998 and 1999 that BMS had some involvement in the project, though this does not appear to have been confirmed by company sources [&lt;ulink linkID="310387" linkType="reference"&gt;310387&lt;/ulink&gt;], [&lt;ulink linkID="337315" linkType="reference"&gt;337315&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 1998, Gruntal predicted Sepracor's sales revenues and royalties at $20 million in 1999 rising to $50 million in 2001 [&lt;ulink linkID="316356" linkType="reference"&gt;316356&lt;/ulink&gt;]. In February 1999, Deutsche Bank predicted Lilly's sales revenues at $250 million in 2002, rising to 500 million in 2003 [&lt;ulink linkID="316821" linkType="reference"&gt;316821&lt;/ulink&gt;]. In August 2000, Merrill Lynch predicted &lt;ulink linkID="17824" linkType="Drug"&gt;R-fluoxetine&lt;/ulink&gt; sales of $5 million in 2002, rising to $65 million in 2004 [&lt;ulink linkID="383230" linkType="reference"&gt;383230&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-10-20T00:00:00.000Z</StatusDate><Source id="386245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-10-20T00:00:00.000Z</StatusDate><Source id="386245" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-10-15T00:00:00.000Z</StatusDate><Source id="301439" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-06-01T00:00:00.000Z</StatusDate><Source id="337315" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19858">Sunovion Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-05-08T11:34:21.000Z</StatusDate><Source id="284630" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-07T00:00:00.000Z</StatusDate><Source id="386245" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-06-01T00:00:00.000Z</StatusDate><Source id="337315" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-06-01T00:00:00.000Z</StatusDate><Source id="337315" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-12-08T00:00:00.000Z</StatusDate><Source id="308357" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17810">Eli Lilly &amp; Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20268">Sumitomo Chemical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CNCC[C@H](c1ccccc1)Oc2ccc(cc2)C(F)(F)F</Smiles><Smiles>CNCC[C@H](c1ccccc1)Oc2ccc(cc2)C(F)(F)F.Cl</Smiles></StructureSmiles><Deals><Deal id="183730" title="Sepracor and Lilly to codevelop (R)-fluoxetine (Prozac isomer) worldwide"></Deal></Deals><PatentFamilies><PatentFamily id="1200245" number="WO-09213452" title="Methods of use and compositions of r(-) fluoxetine."></PatentFamily><PatentFamily id="170709" number="WO-09949857" title="Stable dosage forms of fluoxetine and its enantiomers."></PatentFamily><PatentFamily id="1879177" number="WO-02069951" title="Compositions and methods for management of serotonin-mediated disorders"></PatentFamily><PatentFamily id="1979559" number="WO-00007976" title="Fluoxetine process from benzoylacetonitrile."></PatentFamily><PatentFamily id="2014763" number="EP-00449562" title="Use of R-fluoxetine as selective serotonin IC-receptor ligands."></PatentFamily><PatentFamily id="2022362" number="WO-00024399" title="Compositions and methods employing R(-) fluoxetine and other active ingredients"></PatentFamily><PatentFamily id="500096" number="WO-09961014" title="Compositions and methods employing R (-) fluoxetine and other active ingredients."></PatentFamily><PatentFamily id="505156" number="WO-00193844" title="Phamaceutical compositions and their use"></PatentFamily><PatentFamily id="763701" number="WO-09967196" title="Fluoxetine process from benzoylpropionic acid."></PatentFamily><PatentFamily id="834027" number="WO-09641633" title="Methods Of Treating Cold And Allergic Rhinitis"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"></CompanyLink><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>